All News

Cush ACR learning computer online

Day 2 Report from ACR21

Jack Cush, MD

This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.

Read Article
ACR Best

ACR21 Best Abstracts - Day 2

Jack Cush, MD

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article
acr_session2.jpeg

Opening Day Report

Jack Cush, MD

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Read Article
YouTube Still

RheumNow Podcast – ACR Convergence Begins (11.5.2021)

Jack Cush, MD

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.

Read Article
Telemedicine black computer

Negative Concerns of Telemedicine in Rheumatology

Jack Cush, MD

Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.

Read Article
URI.infection.COrona.jpg

Infection Rates in Psoriatic Arthritis Patients on Biologics Have Decreased

ACR

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.

Read Article
vaccine.jpg

Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose

ACR

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a t

Read Article
RheumNow Podcast square

RheumNow Podcast – Like Father, Like Daughter (10.29.2021)

Jack Cush, MD

Bad things happen when our patients go into the ICU and it's not always due to the disease. Good things happen when we rise from sitting. And guess what? Rheumatologists are setting cardiology straight about hydroxychloroquine and chloroquine. This, and a special recognition of parent-child rheumatologists, along with the news and articles from this week on RheumNow.

Read Article
PSO.Palmoplantar.jpg

Biologic Use and the Risk of Serious Infection in Psoriasis Patients

Jack Cush, MD

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or apremila

Read Article
Knowledge Bowl at #ACR21 ⭐️In this triad seen in TB arthritis, one can see juxta-articular osteopenia, peripheral osseous erosions, and late joint space narrowing ➡️Phermister's triad @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#volcosporin good ~lupus nephritis added to #MMF but underbelly - side effects like but ?less than #cyclosporin. #FDA update - ⬆️hypertension and nephrotoxicity, infection #ACR21 @RheumNow https://t.co/w5nLLSTlrB

Links:

Janet Pope Janetbirdope ( View Tweet)

#PJP prophylaxis debate at #lupus hub if on #prednisone + immune suppression. #SLE has ⤴️septra side effects. Don’t know right answer. NNT v NNH is unknown. I don’t use it in #SLE. @RheumNow #ACR21 8M212

Janet Pope Janetbirdope ( View Tweet)

A worthwhile point: despite historic concerns, in the modern era TNFi can used safely & well in HIV pts 18y follow-up, all pts high CD4 (their starting criteria: CD4>200, VL <60,000) no reported opportunistic infx good arthritis response #ACR21 ABST0965 @RheumNow @CCalabreseDO https://t.co/5pbRg63ubr
David Liew drdavidliew ( View Tweet)
HZV in pts w/ #rheumatic dse by Dr CCMok et al 🔸Prevalence rates of HZV infxn (per 100py): SLE 1.7, RA 0.64, other RDs 0.76 🔸RFs assoc'd w/1st HZV infection 📌#SLE dx, serum albumin, serum creatinine; ⬆lympho/neutro ratio, CYC & Prednisolone use @RheumNow #ACR21 abs0862 https://t.co/TXRmoBBDXK
sheila RHEUMarampa ( View Tweet)
Abst 0562 Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis - Prevalence is high - Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI) #ACR21 @RheumNow https://t.co/UftoFllE1v
Akhil Sood MD AkhilSoodMD ( View Tweet)
Role of anti-CK antibodies: 👉⬆️susceptibility to severe mycobacterial dz & opportunistic infx (similar to HIV) 👉causes an indeterminate quantiferon (no response to mitogen) 👉initiated by infx➡️anti-Noc2 Ab➡️cross react with IFN➡️IFN-Ab 👉⬆️severity of #COVID19 #ACR21 1/2 https://t.co/5NHQpwQw6X
TheDaoIndex KDAO2011 ( View Tweet)
It is always difficult to distinguish infection and disease flares in autoinflammatory syndromes = 25 pt sJIA study at #ACR21 showing serum procalcitonin levels are useful when >0.95ng/ml @StillsDis_411 @rheumnow #abst0252

Bella Mehta bella_mehta ( View Tweet)

@jhrheumatology Dr. Petri at #ACR21 Great Debate. Safety issues with Voclosporin: 1) Nephrotoxicity 2) Infection 3) CV Risk Factors 4) Malignancy 5) Neurologic toxicity 6) Osteoporosis 7) Drug interactions 8) Deaths 9) Pregnancy contraindication @RheumNow https://t.co/wjluivmKNt
Eric Dein ericdeinmd ( View Tweet)
Rheumatic pts admitted to ICU, #SLE is most common & Sepsis most common reason. 80 ARD pts adm to ICU: Dx were SLE (42%), RA (26%), vasculitis (12%) FOR Sepsis (31%), (10%) CHF (10%). 20% died in ICU, 5% 30d after ICU, 7.5% w/in 1 yr https://t.co/lX0m3vOukI

Links:

Dr. John Cush RheumNow ( View Tweet)

From March to Dec 2020, study of 116K COVID pts saw monthly rates of hospitalization (105/100K), ICU admits (20/100K), & death (12/100K) -peaked 12/20. Highest w/ age >65yrs, hispanics, blacks. Remdesivir incr 1.7% to 54%; Steroids 19% to 74.2% https://t.co/5pzu74YIz6

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×